CastellaniP., VialeG., DorcarattoA., NicolòG., KaczmarekJ., QuerzéG., ZardiL.: The fibronectin isoform containing the ED-B oncofetal domain: a marker of angiogenesis.Int J Cancer, 59: 612–618, 1994.
5.
CarnemollaB., BalzaE., SiriA., ZardiL., NicotraM.R., BigottiA., NataliP.G.: A tumor-associated fibronectin isoform generated by alternative splicing of messenger RNA precursors.J Cell Biol, 108: 1139–1148, 1989.
6.
ShawlertD.L., BartholomewR.M., SmithL.M., DillmanR.O.: Human immune response to multiple injections of murine monoclonal IgG.J Immunol, 135: 1530–1535, 1985.
7.
MillerR.A., OseroffA.R., StratteP.T., LevyR.: Monoclonal antibody therapeutic trials, in seven patients with T-cell lymphoma.Blood, 62: 988–995, 1983.
8.
HakimiJ., ChizzoniteR., LukeD.R., FamillettiP.C., BailonP., KondasJ.A., PilsonR.S., LinP., WeberD.V., Spence: Reduced immunogenicity and improved pharmacokinetics of humanized anti-Tac in cynomolgus monkeys.J Immunol, 147: 1352–1359, 1991.
9.
StephensS., EmtageS., VetterleinO., ChaplinL., BebbingtonC., NesbittA., SopwithM., AthwalD., NovakC., BodmerM.: Comprehensive pharmacokinetics of a humanized antibody and analysis of residual anti-idiotypic responses.Immunology, 85: 668–674, 1995.
10.
RiechmannL., ClarkM., WaldmannH., WinterG.: Reshaping human antibodies for therapy.Nature, 332: 323–327, 1988.
11.
JunghansR.P., WaldmannT.A., LandolfiN.F., AvdalovicN.M., SchneiderW.P., QueenC.: Anti-Tac-H, a humanized antibody to the interleukin 2 receptor with new features for immunotherapy in malignant and immune disorders.Cancer Res, 50: 1495–1502, 1990.
NilsonnF., TarliL., VitiF., NeriD.: The use of phage display for the development of tumour targeting agents.Advanced Drug Delivery Reviews, 43: 165–196, 2000.
15.
WinterG., GriffithsA.D., HawkinsR.E., HoogenboomH.R.: Making antibodies by phage display technology.Annu Rev Immunol, 12: 433–455, 1994.
16.
ReichertJ.M.: Monoclonals antibodies in the clinic.Nature Biotech, 19: 819–822, 2001.
17.
HulsG.A., HeijnenI.A.F.M., CuomoM.E., KoningsbergerJ.C., WiegmanL., BoelE., Van der Vuurst de VriesA.R., LoysonS.A.J., HelfrichW., Van Berge HenegouwenG.P., Van MeijerM., De KruifJ., LogtenbergT.: A recombinant, fully human monoclonal antibody with antitumor activity constructed from phage-displayed antibody fragments.Nature Biotech, 17: 276–281, 1999.
18.
PiniA., VitiF., SantucciA., CarnemollaB., ZardiL., NeriP., NeriD.: Design and use of a phage display library. Human antibodies with subnanomolar affinity against a marker of angiogenesis eluted from a two-dimensional gel.J Biol Chem, 273: 21769–21776, 1998.
19.
ZardiL., CarnemollaB., SiriA., PetersenT.E., PaolellaG., SebastioG., BaralleF.E.: Transformed human cells produce a new fibronectin isoform by preferential alternative splicing of a previously unobserved exon.EMBO J, 6, 2337–2342, 1987.
20.
CarnemollaB., NeriD., CastellaniP., LepriniA., NeriG., PiniA., WinterG., ZardiL.: Phage antibodies with pan-species recognition of the oncofoetal angiogenesis marker fibronectin ED-B domain.Int J Cancer, 68: 397–405, 1996.
21.
TarliL., BalzaE., VitiF., BorsiL., CastellaniP., BerndorffD., DinkelborgL., NeriD., ZardiL.: A high-affinity human antibody that targets tumoral blood vessels.Blood;94: 192–198, 1999.
22.
VitiF., TarliL., GiovannoniL., ZardiL., NeriD.: Increased binding affinity and valence of recombinant antibody fragments lead to improved targeting of tumoral angiogenesis.Cancer Res, 59: 347–353, 1999.
23.
NeriD., CarnemollaB., NissimA., LepriniA., QuerzèG., BalzaE., PiniA., TarliL., HalinC., NeriP., ZardiL., WinterG.: Targeting by affinity-matured recombinant antibody fragments of an angiogenesis associated fibronectin isoform.Nature Biotech, 15: 1271–1275, 1997
24.
DemartisS., TarliL., BorsiL., ZardiL., NeriD.: In vivo targeting of tumour neo-vasculature by a radiohalogenated human antibody fragment specific for the ED-B domain of Fibronectin.Eur J Nucl Med, 28; 4534–4539, 2001.
25.
BirchlerM-B, VitiF., ZardiL., SpiessB., NeriD.: Selective targeting and photocoagulation of ocular angiogenesis mediated by a phage-derived human antibody fragment.Nat Biotechnol, 17: 984–988, 1999.
26.
NilssonF., KosmehlH., ZardiL., NeriD.: Targeted delivery of tissue factor to the ED-B domain of fibronectin, a marker of angiogenesis, mediates the infraction of solid tumors in mice.Cancer Res, 61: 711–716, 2001.
27.
CarnemollaB., BorsiL., BalzaE., CastellaniP., MeazzaR., BerndtA., FerriniS., KosmehlH., NeriD., ZardiL.: Enhancement of the anti-tumor properties of Interleukin-2 by its targeted delivery to the tumor blood vessel extracellular matrix.Blood, in press.
28.
TannenbaumC.S., HamiltonT.A.: Immune-inflammatory mechanisms in IFN gamma-mediated anti-tumor activity.Semin Cancer Biol2000, 10: 113–123.
